Company: SYRA
Filing Date: 2025-03-11
Form Type: 10-K
Source: 0001493152-25-009873
Chunk: 183

Company: Syra Health Corp
Filing Date: 2025-03-11
Form: 10-K
Item: Item 1
Chunk 183
---
 financial statement income, effective for tax years beginning after December 31, 2022, and a 1%
excise tax on share repurchases occurring after December 31, 2022. We may be subject to the new excise tax with respect to any redemptions
of our stock. Further, the current administration had previously set forth several tax proposals that would, if enacted, make further
significant changes to U.S. tax laws (including provisions enacted pursuant to the Tax Act). It is unclear whether these or similar changes
will be enacted and, if enacted, how soon any such changes could take effect. The passage of any legislation as a result of these proposals
and other similar changes in U.S. federal income tax laws could adversely affect our business and future profitability. Investors are
urged to consult with their legal and tax advisors with respect to any such legislation and the potential tax consequences of holding
our securities.

Our
use and development of artificial intelligence products may result in reputational harm and liability.

We
incorporate artificial intelligence in some of the products we offer. For example, some of our targeted education approaches include
the utilization of artificial intelligence tools to provide real-time information to customers, and we intend to offer an artificial
intelligence chatbot to facilitate and provide end-to-end query resolution for patients. The field of artificial intelligence is rapidly
developing, both technologically and from a regulatory and legal standpoint. As we incorporate this technology into our products we may
experience unexpected outcomes or impacts related to the technology, creating reputational, legal and regulatory risks.

Risks
Related to Intellectual Property

The
protection of our intellectual property requires substantial resources and protections of our proprietary rights may not be adequate.

We
rely or intend to rely upon a combination of trade secret, copyright and trademark laws, patents, license agreements, confidentiality
procedures, nondisclosure agreements and technical measures designed to protect the intellectual property used in our business. The steps
we have taken to protect and enforce our proprietary rights and intellectual property may not be adequate. For instance, our agreements
with employees, consultants and others who develop intellectual property for or on behalf of us could be breached and could result in
our trade secrets and confidential information being publicly disclosed. We may not have adequate remedies for any such breach. Third
parties also may infringe upon or misappropriate our intellectual property rights. If we believe a third party has misappropriated our
intellectual property, litigation may be necessary to enforce